Fierce Pharma June 7, 2024
Fraiser Kansteiner

Thanks to respiratory syncytial virus (RSV) shot Arexvy’s new label expansion into a slightly younger pool of adults, GSK is more confident than ever that its vaccine will be able to conquer the competition.

On Friday, the FDA approved Arexvy for RSV prevention in adults ages 50 to 59 who are at increased risk of developing RSV disease. The green light marks Arexvy’s first new approval since the vaccine’s original nod to prevent lower respiratory tract disease (LRTD) caused by RSV in adults ages 60 and older last May.

According to GSK’s research, there are about 13 million people between the ages of 50 to 59 in the United States with underlying conditions that place them at higher risk of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article